Decellularization technology developer MiroMatrix Medical raised $23 million in a new round of equity financing, according to an SEC filing posted last week.
MiroMatrix develops and utilizes a proprietary technology to remove cells, or decellularize, organs and tissue.
Currently, MiroMatrix has 510(k) clearance for its MiroMesh biological mesh used during hernia repair procedures and as a general wound treatment, and plans to submit additional applications for other indications, according to its website.
Help employers find you! Check out all the jobs and post your resume.
